Pharmaceutical Shares of USA-based Sorrento Therapeutics fell more than 9% to $3.88 by close of trading on Monday, after the company announced that, after reviewing the latest acquisition proposal received earlier this month, in consultation with its advisors, Sorrento’s board of directors determined that the $7.00 per share offer significantly undervalues Sorrento and is not in the best interest of the company’s stockholders. 28 January 2020